LEVATIO Therapeutics

LEVATIO Therapeutics is a biotechnology company pioneering a novel class of oral biologics designed to modulate the immune system through the gut-associated lymphoid tissue (GALT). The company's proprietary platform utilizes engineered, non-pathogenic bacteria to deliver therapeutic payloads, such as short hairpin RNA (shRNA) or proteins, directly to immune cells in the gastrointestinal tract. By leveraging the natural role of the GALT as a primary site for immune regulation, LEVATIO aims to develop highly targeted therapies for oncology and autoimmune disorders. Their approach offers the potential for systemic immune modulation with the convenience of oral administration and a favorable safety profile.